324 related articles for article (PubMed ID: 30859608)
1. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Pegourie B; Karlin L; Benboubker L; Orsini-Piocelle F; Tiab M; Auger-Quittet S; Rodon P; Royer B; Leleu X; Bareau B; Cliquennois M; Fuzibet JG; Voog E; Belhadj-Merzoug K; Decaux O; Rey P; Slama B; Leyronnas C; Zarnitsky C; Boyle E; Bosson JL; Pernod G;
Am J Hematol; 2019 Jun; 94(6):635-640. PubMed ID: 30859608
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
[TBL] [Abstract][Full Text] [Related]
3. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
4. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Storrar NPF; Mathur A; Johnson PRE; Roddie PH
Br J Haematol; 2019 Apr; 185(1):142-144. PubMed ID: 29785771
[No Abstract] [Full Text] [Related]
6. [Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy].
Oka S; Takeuchi S; Shiragami H; Hamahata K; Nohgawa M
Rinsho Ketsueki; 2017; 58(1):37-41. PubMed ID: 28190864
[TBL] [Abstract][Full Text] [Related]
7. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
8. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
9. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
10. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
12. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H
Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607
[TBL] [Abstract][Full Text] [Related]
13. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Patton D; Harrell S; Hall R; Wyatt H; Piazza G
Front Oncol; 2019; 9():45. PubMed ID: 30873378
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.
Costa BA; Costa TA; Saravia SD; Felix N; Tan CR; Korde N; Richter J
Am J Hematol; 2024 Jun; 99(6):1056-1065. PubMed ID: 38488702
[TBL] [Abstract][Full Text] [Related]
16. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
18. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
